NASDAQ:NEO - NeoGenomics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.16 +0.35 (+2.53 %)
(As of 07/19/2018 01:30 PM ET)
Previous Close$13.97
Today's Range$13.88 - $14.34
52-Week Range$7.08 - $14.61
Volume14,575 shs
Average Volume461,411 shs
Market Capitalization$1.13 billion
P/E Ratio237.17
Dividend YieldN/A
Beta0.52
NeoGenomics logoNeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Debt-to-Equity Ratio0.53
Current Ratio2.03
Quick Ratio1.85

Price-To-Earnings

Trailing P/E Ratio237.17
Forward P/E Ratio128.73
P/E Growth6.65

Sales & Book Value

Annual Sales$258.61 million
Price / Sales4.41
Cash Flow$0.4843 per share
Price / Cash29.24
Book Value$2.15 per share
Price / Book6.59

Profitability

EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins-0.86%
Return on Equity3.19%
Return on Assets1.58%

Miscellaneous

Employees1,030
Outstanding Shares80,620,000
Market Cap$1,125.41

The Truth About Cryptocurrencies

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, May, 1st. The medical research company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The medical research company had revenue of $63.40 million for the quarter, compared to analyst estimates of $62.31 million. NeoGenomics had a positive return on equity of 3.19% and a negative net margin of 0.86%. NeoGenomics's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS. View NeoGenomics' Earnings History.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $0.15-$0.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.17. The company issued revenue guidance of $260-$272 million, compared to the consensus revenue estimate of $266.42 million.

What price target have analysts set for NEO?

8 equities research analysts have issued 1 year price objectives for NeoGenomics' stock. Their forecasts range from $9.00 to $24.00. On average, they expect NeoGenomics' share price to reach $17.50 in the next year. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Ratings for NeoGenomics.

What is the consensus analysts' recommendation for NeoGenomics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:
  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/19/2018)
  • 2. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
  • Mr. Steven C. Jones, Exec. VP & Director (Age 55)
  • Dr. Maher Albitar, Chief Medical Officer and Director of R&D (Age 63)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)
  • Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 47)

Has NeoGenomics been receiving favorable news coverage?

News stories about NEO stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeoGenomics earned a media sentiment score of 0.06 on Accern's scale. They also gave media headlines about the medical research company an impact score of 45.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (1.27%) and First United Bank Trust (0.04%). Company insiders that own NeoGenomics stock include Alison L Hannah, Jennifer Balliet, Maher Albitar, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and First United Bank Trust. Company insiders that have sold NeoGenomics company stock in the last year include Jennifer Balliet, Robert J Shovlin, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $14.22.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $1.13 billion and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]


MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.